Date: 07 Dec 2005

Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Background

The goal of this study was to determine the optimal treatment parameters for the ablation of human esophageal epithelium using a balloon-based bipolar radiofrequency (RF) energy electrode.

Methods

Immediately prior to esophagectomy, subjects underwent esophagoscopy and ablation of two separate, 3-cm long, circumferential segments of non-tumor-bearing esophageal epithelium using a balloon-based bipolar RF energy electrode (BARRX Medical, Inc., Sunnyvale, CA, USA). Subjects were randomized to one of three energy density groups: 8, 10, or 12 J/cm2. RF energy was applied one time (1×) proximally and two times (2×) distally. Following resection, sections from each ablation zone were evaluated using H&E and diaphorase. Histological endpoints were complete epithelial ablation (yes/no), maximum ablation depth, and residual ablation thickness after tissue slough. Outcomes were compared according to energy density group and 1× vs 2× treatment.

Results

Thirteen male subjects (age, 49–85 years) with esophageal adenocarcinoma underwent the ablation procedure followed by total esophagectomy. Complete epithelial removal occurred in the following zones: 10 J/cm2 (2×) and 12 J/cm2 (1× and 2×). The maximum depth of injury was the muscularis mucosae: 10 and 12 J/cm2 (both 2×). A second treatment (2×) did not significantly increase the depth of injury. Maximum thickness of residual ablation after tissue slough was only 35 μm.

Conclusions

Complete removal of the esophageal epithelium without injury to the submucosa or muscularis propria is possible using this balloon-based RF electrode at 10 J/cm2 (2×) or 12 J/cm2 (1× or 2×). A second application (2×) does not significantly increase ablation depth. These data have been used to select the appropriate settings for treating intestinal metaplasia in trials currently under way.